A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations

Brain Research

Volumn 1344, Issue , 2010, Pages 185-191

  Keller, Lina ^a   Murphy, Charlotte ^a   Wang, Hui Xin ^b   Fratiglioni, Laura ^b   Olin, Maria ^a   Gafvels, Mats ^a   Björkhem, Ingemar ^a   Graff, Caroline ^b   Meaney, Steve ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM GERONTOLOGY RESEARCH CENTER   (Sweden)

^c DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

Alzheimer disease; Cholesterol; Genetic association; HMGCR; Promoter activity; Single nucleotide polymorphism

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; TRANSCRIPTION REGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CASE-CONTROL STUDIES; CELL LINE, TRANSFORMED; CHOLESTEROL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; SWEDEN; TRANSFECTION;

EID: 77953963028     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.04.073     Document Type: Article

References (51)

1. Beffert U., and Poirier J. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann. N.Y. Acad. Sci. 777 (1996) 166-174
2. Björk B.F., Katzov H., Kehoe P., Fratiglioni L., Winblad B., Prince J.A., and Graff C. Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. Neurobiol. Aging 28 (2007) 1374-1380
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
4. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton Jr. V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. Jama 291 (2004) 2821-2827
5. Corder E.H., Saunders A.M., Pericak-Vance M.A., and Roses A.D. There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. Arch. Neurol. 52 (1995) 650-651
6. Corder E.H., Lannfelt L., Bogdanovic N., Fratiglioni L., and Mori H. The role of APOE polymorphisms in late-onset dementias. Cell. Mol. Life Sci. 54 (1998) 928-934
7. Craig S.R., Amin R.V., Russell D.W., and Paradise N.F. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J. Gen. Intern. Med. 15 (2000) 395-399
8. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., and Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118 (2008) 4002-4013
9. Desai P., DeKosky S.T., and Kamboh M.I. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci. Lett. 328 (2002) 9-12
10. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., Wood A.M., Lewington S., Sattar N., Packard C.J., Collins R., Thompson S.G., and Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009) 1993-2000
11. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
12. Hagberg J.M., Wilund K.R., and Ferrell R.E. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol. Genomics 4 (2000) 101-108
13. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., and Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41 (2009) 1088-1093
14. Hartmann T., Kuchenbecker J., and Grimm M.O. Alzheimer's disease: the lipid connection. J. Neurochem. 103 Suppl 1 (2007) 159-170
15. Helisalmi S., Vepsalainen S., Koivisto A.M., Mannermaa A., Iivonen S., Hiltunen M., Kiviniemi V., and Soininen H. Association of CYP46 intron 2 polymorphism in Finnish Alzheimer's disease samples and a global scale summary. J. Neurol. Neurosurg. Psychiatry 77 (2006) 421-422
16. Hennekam R.C. Congenital brain anomalies in distal cholesterol biosynthesis defects. J. Inherit. Metab. Dis. 28 (2005) 385-392
17. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., and Goldstein J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12027-12032
18. Ingelsson M., Jesneck J., Irizarry M.C., Hyman B.T., and Rebeck G.W. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neurosci. Lett. 367 (2004) 228-231
19. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
20. Johansson A., Katzov H., Zetterberg H., Feuk L., Johansson B., Bogdanovic N., Andreasen N., Lenhard B., Brookes A.J., Pedersen N.L., Blennow K., and Prince J.A. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum. Genet. 114 (2004) 581-587
21. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Bmj 322 (2001) 1447-1451
22. Kotti T.J., Ramirez D.M., Pfeiffer B.E., Huber K.M., and Russell D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3869-3874
23. Lagergren M., Fratiglioni L., Hallberg I.R., Berglund J., Elmstahl S., Hagberg B., Holst G., Rennemark M., Sjolund B.M., Thorslund M., Wiberg I., Winblad B., and Wimo A. A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). Aging Clin. Exp. Res. 16 (2004) 158-168
24. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., and Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41 (2009) 1094-1099
25. Llorca J., Rodriguez-Rodriguez E., Dierssen-Sotos T., Delgado-Rodriguez M., Berciano J., and Combarros O. Meta-analysis of genetic variability in the beta-amyloid production, aggregation and degradation metabolic pathways and the risk of Alzheimer's disease. Acta Neurol. Scand. 117 (2008) 1-14
26. Love S., Bridges L.R., and Case C.P. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 118 Pt 1 (1995) 119-129
27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
28. Mielke M.M., Zandi P.P., Sjogren M., Gustafson D., Ostling S., Steen B., and Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64 (2005) 1689-1695
29. Naidu A., Xu Q., Catalano R., and Cordell B. Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res. 958 (2002) 100-111
30. Ordovas J.M., and Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr. Opin. Lipidol. 13 (2002) 113-117
31. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lutjohann D., Ghebremedhin E., Hegi T., Pasch T., Traxler M., Bruhl A., Benussi L., Binetti G., Braak H., Nitsch R.M., and Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60 (2003) 29-35
32. Pfrieger F.W. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. Bioessays 25 (2003) 72-78
33. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., and Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342 (1993) 697-699
34. Porcellini E., Calabrese E., Guerini F., Govoni M., Chiappelli M., Tumini E., Morgan K., Chappell S., Kalsheker N., Franceschi M., and Licastro F. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neurosci. Lett. 416 (2007) 66-70
35. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., Hazzard W.R., Zandi P.P., Burke G.L., Lyketsos C.G., Bernick C., and Kuller L.H. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 62 (2005) 1047-1051
36. Recuero M., Vicente M.C., Martinez-Garcia A., Ramos M.C., Carmona-Saez P., Sastre I., Aldudo J., Vilella E., Frank A., Bullido M.J., and Valdivieso F. A free radical-generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease. Aging Cell 8 (2009) 128-139
37. Reid P.C., Urano Y., Kodama T., and Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell. Mol. Med. 11 (2007) 383-392
38. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., Xu L., Aschmies S., Kirksey Y., Hu Y., Wagner E., Parratt A., Xu J., Li Z., Zaleska M.M., Jacobsen J.S., Pangalos M.N., and Reinhart P.H. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28 (2008) 11445-11453
39. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
40. Sakakura Y., Shimano H., Sone H., Takahashi A., Inoue N., Toyoshima H., Suzuki S., and Yamada N. Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem. Biophys. Res. Commun. 286 (2001) 176-183
41. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
42. Solomon A., Kareholt I., Ngandu T., Winblad B., Nissinen A., Tuomilehto J., Soininen H., and Kivipelto M. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68 (2007) 751-756
43. Solomon A., Leoni V., Kivipelto M., Besga A., Oksengard A.R., Julin P., Svensson L., Wahlund L.O., Andreasen N., Winblad B., Soininen H., and Bjorkhem I. Plasma levels of 24 S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci. Lett. 462 (2009) 89-93
44. StatCorp. Intercooled Stata 9.2 for Windows (2006), College Station, USA TX 77845
45. Stewart R., White L.R., Xue Q.L., and Launer L.J. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol. 64 (2007) 103-107
46. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1977-1981
47. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
48. van Es M.A., and van den Berg L.H. Alzheimer's disease beyond APOE. Nat. Genet. 41 (2009) 1047-1048
49. Willer C.J., Sanna S., Jackson A.U., Scuteri A., Bonnycastle L.L., Clarke R., Heath S.C., Timpson N.J., Najjar S.S., Stringham H.M., Strait J., Duren W.L., Maschio A., Busonero F., Mulas A., Albai G., Swift A.J., Morken M.A., Narisu N., Bennett D., Parish S., Shen H., Galan P., Meneton P., Hercberg S., Zelenika D., Chen W.M., Li Y., Scott L.J., Scheet P.A., Sundvall J., Watanabe R.M., Nagaraja R., Ebrahim S., Lawlor D.A., Ben-Shlomo Y., Davey-Smith G., Shuldiner A.R., Collins R., Bergman R.N., Uda M., Tuomilehto J., Cao A., Collins F.S., Lakatta E., Lathrop G.M., Boehnke M., Schlessinger D., Mohlke K.L., and Abecasis G.R. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40 (2008) 161-169
50. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
51. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62 (2005) 217-224